108 related articles for article (PubMed ID: 25196949)
21. Thalidomide therapy for aggressive histiocytic lesions in the pediatric population.
Bailey KM; Castle VP; Hummel JM; Piert M; Moyer J; McAllister-Lucas LM
J Pediatr Hematol Oncol; 2012 Aug; 34(6):480-3. PubMed ID: 22810753
[TBL] [Abstract][Full Text] [Related]
22. Coexistence of hydroa vacciniforme and malignant lymphoma.
Oono T; Arata J; Masuda T; Ohtsuki Y
Arch Dermatol; 1986 Nov; 122(11):1306-9. PubMed ID: 3490832
[TBL] [Abstract][Full Text] [Related]
23. Ophthalmic findings in a patient with CD8-positive T cell lymphoma and a hydroa vacciniforme-like eruption.
Zamecki KJ; Friedman AH; Raab EL
Br J Ophthalmol; 2010 Sep; 94(9):1266-7. PubMed ID: 20530183
[No Abstract] [Full Text] [Related]
24. Photodermatoses: Kids are not just little people.
Naka F; Shwayder TA; Santoro FA
Clin Dermatol; 2016; 34(6):724-735. PubMed ID: 27968932
[TBL] [Abstract][Full Text] [Related]
25. Hydroa vacciniforme presenting in an adult successfully treated with cyclosporin A.
Blackwell V; McGregor JM; Hawk JL
Clin Exp Dermatol; 1998 Mar; 23(2):73-6. PubMed ID: 9692310
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of ω-3 polyunsaturated fatty acids for the treatment of refractory hydroa vacciniforme.
Durbec F; Reguiaï Z; Léonard F; Pluot M; Bernard P
Pediatr Dermatol; 2012; 29(1):118-9. PubMed ID: 21967631
[TBL] [Abstract][Full Text] [Related]
27. [Hydroa vacciniforme, a well defined photodermatosis (clinical, histopathological and photobiological aspects, apropos of 3 personal cases].
Botella R; Mascaró JM; Castillo V
Med Cutan Ibero Lat Am; 1976; 4(1):53-62. PubMed ID: 988445
[TBL] [Abstract][Full Text] [Related]
28. Response to thalidomide in chemotherapy-resistant cutaneous T-cell lymphoma.
Oxberry SG; Johnson MJ
Clin Oncol (R Coll Radiol); 2006 Feb; 18(1):86-7. PubMed ID: 16477929
[No Abstract] [Full Text] [Related]
29. A survey examination of patients with hydroa vacciniforme.
Kil EH; DeLeo VA
Cutis; 2011 Nov; 88(5):245-53. PubMed ID: 22272489
[TBL] [Abstract][Full Text] [Related]
30. Epstein-Barr virus involvement in the pathogenesis of hydroa vacciniforme: an assessment of seven adult patients with long-term follow-up.
Verneuil L; Gouarin S; Comoz F; Agbalika F; Creveuil C; Varna M; Vabret A; Janin A; Leroy D
Br J Dermatol; 2010 Jul; 163(1):174-82. PubMed ID: 20367637
[TBL] [Abstract][Full Text] [Related]
31. [Bazin's hydroa vacciniforme : photobiological and metabolic study in 3 cases, and discussion on etiopathogenicity (author's transl)].
Rotteleur G; Thomas P; Desmons F
Sem Hop; 1981 May 8-15; 57(17-18):869-76. PubMed ID: 6262924
[TBL] [Abstract][Full Text] [Related]
32. Hydroa vacciniforme with eye involvement: report of two cases.
Mortazavi H; Hejazi P; Aghazadeh N; Esfandiari H; Ghanadan A; Jahanzad I
Pediatr Dermatol; 2015; 32(1):e39-41. PubMed ID: 25209448
[TBL] [Abstract][Full Text] [Related]
33. NK-/T-cell lymphoma resembling hydroa vacciniforme with positive CD4 marker expression: a diagnostic difficulty.
Zhang G; Bai HX; Yang L; Ma MH; Su Y; Luo Y; Wen H; Lu Q; Xiao R
Am J Dermatopathol; 2013 Feb; 35(1):94-7. PubMed ID: 22885552
[TBL] [Abstract][Full Text] [Related]
34. Antiviral therapy in children with hydroa vacciniforme.
Lysell J; Wiegleb Edström D; Linde A; Carlsson G; Malmros-Svennilson J; Westermark A; Andersson J; Wahlgren CF
Acta Derm Venereol; 2009; 89(4):393-7. PubMed ID: 19688153
[TBL] [Abstract][Full Text] [Related]
35. A novel, noninvasive diagnostic probe for hydroa vacciniforme and related disorders: detection of latency-associated Epstein-Barr virus transcripts in the crusts.
Yamamoto T; Tsuji K; Suzuki D; Morizane S; Iwatsuki K
J Microbiol Methods; 2007 Feb; 68(2):403-7. PubMed ID: 17141343
[TBL] [Abstract][Full Text] [Related]
36. Primary cutaneous Epstein-Barr virus-associated T-cell lymphoproliferative disorder-2 cases with unusual, prolonged clinical course.
Park S; Lee DY; Kim WS; Ko YH
Am J Dermatopathol; 2010 Dec; 32(8):832-6. PubMed ID: 20595887
[TBL] [Abstract][Full Text] [Related]
37. Hydroa vacciniforme-like primary cutaneous CD8-positive T-cell lymphoma.
Feng S; Jin P; Zeng X
Eur J Dermatol; 2008; 18(3):364-5. PubMed ID: 18474490
[No Abstract] [Full Text] [Related]
38. Pathogenic link between hydroa vacciniforme and Epstein-Barr virus-associated hematologic disorders.
Iwatsuki K; Satoh M; Yamamoto T; Oono T; Morizane S; Ohtsuka M; Xu ZG; Suzuki D; Tsuji K
Arch Dermatol; 2006 May; 142(5):587-95. PubMed ID: 16702496
[TBL] [Abstract][Full Text] [Related]
39. Immunohistochemical localization of cellular NFATc1 does not predict clinical responses to ciclosporin in subcutaneous panniculitis-like T-cell non-Hodgkin lymphoma.
Tauro S; Maccallum S; Groves MJ; Rojnuckarin P; Assanasen T; Feldman AL; Robson A; Marschalkó M; Kini H; Alzolibani AA; Al Robaee A; Al Shobaili HA; Alfawzan S; Goodlad JR; Kernohan N; Hummel M; Sterry W; Assaf C
Br J Dermatol; 2010 Apr; 162(4):887-9. PubMed ID: 20096007
[No Abstract] [Full Text] [Related]
40. Treatment of cutaneous sarcoidosis with thalidomide.
Nguyen YT; Dupuy A; Cordoliani F; Vignon-Pennamen MD; Lebbé C; Morel P; Rybojad M
J Am Acad Dermatol; 2004 Feb; 50(2):235-41. PubMed ID: 14726878
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
